Abstract:Vasohibin-1 is an intrinsic angiogenesis inhibitor, and is expressed in endothelial cells via induction by pro-angiogenesis factors. It is known to inhibit several processes of angiogenesis, with different mechanisms from extrinsic angiogenesis inhibitors. Vasohibin-2 is mainly expressed by mononuclear cells which have been mobilized from bone marrow. It not only promotes angiogenesis, but also modulates the releases of FGF-2 and VEGF, which are the two major inducers for vasohibin1. Hypoxic environment induces the expression of hypoxia-inducible Factor 1α with a result of VEGF release nearly in all tumor cell lines and tissues. However, it has been observed that hypoxia reduces the inducible effects of VEGF on vasohibin, which indicates that a complicated mechanism exists in the angiogenesis. Vasohibin and its family members play important roles in both the physiological and pathological procedures, in contrary but complementary patterns. Furthermore, human aortic smooth muscle cells and fibroblast have also been detected to express vasohibin on a moderate to weak scale range. Recently, the results of an increasing number of studies in vivo have shown that vasohibin can also be detected in several cancers, and is associated with micro-vessel densities, histology grades, invasions, poor clinical features, metastasis, and dissemination in abdominal cavities, as well as EMT. In more recent reports, it has been confirmed that, along with being angiogenesis regulators, a variety of other roles have been associated with this family. The focus of this study was the upstream regulatory mechanisms of vasohibin expressions, and their role in regard to the downstream target proteins of vasohibin, especially in carcinoma. Vasohibin is considered to be an original angiogenesis inhibitor, and has a much broader significance in pathological processes. It can be taken as an independent prognostic factor, as well as a potential strategy for cancer therapy programs.

The Role of Snake Venom Disintegrins in Angiogenesis

Snake venom disintegrins update: insights about new findings

Role of hydrogen sulphide in physiological and pathological angiogenesis

Emerging anticancer potential and mechanisms of snake venom toxins: A review

Isolation and characterization of ZK002, a novel dual function snake venom protein from Deinagkistrodon acutus with anti-angiogenic and anti-inflammatory properties

Tissue Localization and Extracellular Matrix Degradation by PI, PII and PIII Snake Venom Metalloproteinases: Clues on the Mechanisms of Venom-Induced Hemorrhage

Recombinant RGD-disintegrin DisBa-01 blocks integrin αvβ3 and impairs VEGF signaling in endothelial cells

[Advances in the Research of Mechanisms of Promotion of Vascularization by Angiogenin and Its Application].

Insights into structure and function of CdcVEGFs, the vascular endothelial growth factor from Crotalus durissus collilineatus snake venom

Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor

The Role of Snake Venom Proteins in Inducing Inflammation Post-Envenomation: An Overview on Mechanistic Insights and Treatment Strategies

From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs

Mechanisms of Angiogenesis: Role of Hydrogen Sulphide

A review on snake venom extracellular vesicles: Past to present

Protective effects of novel diazepinone derivatives in snake venom induced sterile inflammation in experimental animals

Using organ-on-a-chip technology to study haemorrhagic activities of snake venoms on endothelial tubules

Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving

Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges

The roles of vasohibin and its family members: Beyond angiogenesis modulators

VEGF in Signaling and Disease: Beyond Discovery and Development

Biomedical applications of synthetic peptides derived from venom of animal origin: A systematic review